West Nile Virus Infections – Pipeline Review, H2 2016

Global Markets Direct’s, ‘West Nile Virus Infections – Pipeline Review, H2 2016’, provides an overview of the West Nile Virus Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for West Nile Virus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for West Nile Virus Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of West Nile Virus Infections

The report reviews pipeline therapeutics for West Nile Virus Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved West Nile Virus Infections therapeutics and enlists all their major and minor projects

The report assesses West Nile Virus Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for West Nile Virus Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for West Nile Virus Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding West Nile Virus Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

CEL-SCI Corporation

Hemispherx Biopharma, Inc.

Kineta, Inc.

Nanotherapeutics, Inc.

Plex Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

West Nile Virus Infections Overview 7

Therapeutics Development 8

Pipeline Products for West Nile Virus Infections - Overview 8

Pipeline Products for West Nile Virus Infections - Comparative Analysis 9

West Nile Virus Infections - Therapeutics under Development by Companies 10

West Nile Virus Infections - Therapeutics under Investigation by Universities/Institutes 11

West Nile Virus Infections - Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

West Nile Virus Infections - Products under Development by Companies 14

West Nile Virus Infections - Products under Investigation by Universities/Institutes 15

West Nile Virus Infections - Companies Involved in Therapeutics Development 16

CEL-SCI Corporation 16

Hemispherx Biopharma, Inc. 17

Kineta, Inc. 18

Nanotherapeutics, Inc. 19

Plex Pharmaceuticals, Inc. 20

West Nile Virus Infections - Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 30

Alferon LDO - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

BG-323 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

CEL-1000 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

FDX-000 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

HydroVax-001 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

interferon alfa-n3 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

KIN-1148 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

KIN-1400 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Monoclonal Antibody for West Nile Virus Infections - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

rintatolimod - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

RL-15A - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecule to Inhibit NS2B-NS3 Protease for Dengue, Zika and West Nile Virus Infection - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Small Molecules for Viral Infections - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Small Molecules to Inhibit NS3 Protease for Dengue and West Nile Virus Infections - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Synthetic Peptide for Dengue Virus and West Nile Virus Infections - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Tatbeclin-1 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

West Nile virus vaccine - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

West Nile virus vaccine - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

West Nile Virus Infections - Dormant Projects 63

West Nile Virus Infections - Product Development Milestones 66

Featured News & Press Releases 66

Jul 06, 2015: NIH-funded vaccine for West Nile Virus enters human clinical trials 66

May 05, 2014: Alferon N Effective Against MERS Virus In-Vitro 67

Sep 12, 2013: Hemispherx Announces Initial Test Results in Biosecurity/Biodefense Arena 67

Sep 06, 2011: Hemispherx Enters Into Strategic Alliance With Armada Health Care For Alferon N Injection 68

Apr 20, 2010: Kineta Scientist to Present Novel Antiviral Research Findings at International Conference 69

Appendix 70

Methodology 70

Coverage 70

Secondary Research 70

Primary Research 70

Expert Panel Validation 70

Contact Us 70

Disclaimer 71

List of Tables

List of Tables

Number of Products under Development for West Nile Virus Infections, H2 2016 8

Number of Products under Development for West Nile Virus Infections – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

West Nile Virus Infections – Pipeline by CEL-SCI Corporation, H2 2016 16

West Nile Virus Infections – Pipeline by Hemispherx Biopharma, Inc., H2 2016 17

West Nile Virus Infections – Pipeline by Kineta, Inc., H2 2016 18

West Nile Virus Infections – Pipeline by Nanotherapeutics, Inc., H2 2016 19

West Nile Virus Infections – Pipeline by Plex Pharmaceuticals, Inc., H2 2016 20

Assessment by Monotherapy Products, H2 2016 21

Number of Products by Stage and Target, H2 2016 23

Number of Products by Stage and Mechanism of Action, H2 2016 25

Number of Products by Stage and Route of Administration, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 29

West Nile Virus Infections – Dormant Projects, H2 2016 63

West Nile Virus Infections – Dormant Projects (Contd..1), H2 2016 64

West Nile Virus Infections – Dormant Projects (Contd..2), H2 2016 65

List of Figures

List of Figures

Number of Products under Development for West Nile Virus Infections, H2 2016 8

Number of Products under Development for West Nile Virus Infections – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 21

Number of Products by Top 10 Targets, H2 2016 22

Number of Products by Stage and Top 10 Targets, H2 2016 22

Number of Products by Top 10 Mechanism of Actions, H2 2016 24

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 24

Number of Products by Routes of Administration, H2 2016 26

Number of Products by Stage and Routes of Administration, H2 2016 26

Number of Products by Molecule Types, H2 2016 28

Number of Products by Stage and Molecule Types, H2 2016 28

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports